Overview

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

Status:
RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.
Phase:
PHASE2
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
Carboplatin
Immune Checkpoint Inhibitors
Paclitaxel
Pemetrexed